FDA approves Abbott’s Libre Duo 10 Day dual glucose-ketone monitor
August 26, 2026
The Libre Duo 10 Day sensor delivers up to ten days of continuous monitoring with ongoing readings, not single-point measurements.
The Libre Duo 10 Day sensor delivers up to ten days of continuous monitoring with ongoing readings, not single-point measurements.
The University of Tokyo and Institute of Science Tokyo’s AI detected diabetes with accuracy >80% from 30-second and five-seconds recordings.
In a new study, Mass General Brigham researchers explore the causes of immune aging, a barrier to successful cancer immunotherapy, and identify a gene that may serve as an age-related prognostic marker and potential target for future cancer therapies.
Poor sleep quality has been linked to cognitive decline, neurodegeneration and Alzheimer’s disease in older adults. A new international study led by Concordia researchers and published in the journal Neurology shows that specific sleep brain waves provide protection against the harmful effects of a brain chemical usually associated with wakefulness and sleep transition.
Bladder cancer claims 220,000 lives globally each year, with symptoms sometimes mistaken for other conditions such as kidney stones. Now researchers have developed an artificial intelligence system that can identify bladder cancer patients up to five years before their official diagnosis, potentially revolutionizing screening for the disease.
Researchers at NYU Abu Dhabi have developed BRIDGE (Biodegradable aRchitected Internal DrainaGE), a biodegradable, 3D-printed gastric stent that could improve treatment for gastric leaks, a serious complication following weight-loss surgery.
Kidney disease is silent in its early stages, progressing without symptoms until the disease is advanced. Researchers in the McKelvey School of Engineering at Washington University in St. Louis, in collaboration with researchers at WashU Medicine and Texas A&M University, have been developing a minimally invasive method to improve diagnosis at earlier stages.
The immune system possesses legions of T cells that, if primed, could hunt down and destroy tumors. Now, a UC San Francisco team has invented a way to do this by combining immune cells grown in the lab with samples from a patient’s tumor. Like giving a scent to a hound dog, it shows the immune system how to go after the cancer.
Inspired by the work of the RNA Therapeutics Institute at UMass Chan Medical School and the development of the COVID vaccine, Marcus Ruscetti, Ph.D., and Chaitanya Naimesh Parikh, Ph.D. ’26, have developed an immunotherapy using a cocktail of messenger RNAs (mRNA) that could potentially transform pancreatic cancer treatment.
The research highlights the role of TEX264, a protein that helps cancer cells remove and degrade PARP1 trapped on DNA following treatment